What is ALS Phase 3 Study Dexpramipexole (KNS-760704)?

Category: Others

false

See also: Clinical Trial

NCT01281189 is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of dexpramipexole in subjects with amyotrophic lateral sclerosis (ALS). Dexpramipexole was previously known as KNS-760704. Other study IDs: EMPOWER, 223AS302, EUDRA CT NO:2010-022818-19.

Side effects

Side effects as an overall problem

Side effects of ALS Phase 3 Study Dexpramipexole (KNS-760704)

Severe
1
Moderate
2
Mild
9
None
25

Commonly reported side effects, conditions, and hospitalizations associated with ALS Phase 3 Study Dexpramipexole (KNS-760704)

Patients
3
Patients
2
Hospitalization
Patients
2
Patients
2
Patients
2

Show all 21 reported side effects

Dosages

Most common dosages (by patients currently using ALS Phase 3 Study Dexpramipexole (KNS-760704))
Dosage
300 mg daily
Patients
16
Dosage
2 daily
Patients
7
Dosage
2 other daily
Patients
3
Dosage
1M,W,F as needed
Patients
1
Dosage
2 intl units daily
Patients
1
Dosage
2 mg daily
Patients
1
Dosage
30 mg daily
Patients
1
Dosage
150 mg daily
Patients
1
Why Patients Stopped Using ALS Phase 3 Study Dexpramipexole (KNS-760704) (multiple reasons could be selected)
Reason
Course of treatment ended
Patients
13
Reason
Other
Patients
10
Reason
Did not seem to work
Patients
4
Reason
Side effects too severe
Patients
3
Reason
Doctor's advice
Patients
2
Reason
Personal research
Patients
1
See all 27 patients who’ve stopped using ALS Phase 3 Study Dexpramipexole (KNS-760704)

Duration

Currently Using ALS Phase 3 Study Dexpramipexole (KNS-760704)
Duration
Patients
Duration
0-1 month
Patients
0
Duration
1-3 months
Patients
0
Duration
3-6 months
Patients
0
Duration
6 months-1 year
Patients
0
Duration
1-2 years
Patients
0
Duration
2 years or more
Patients
3
Stopped Using ALS Phase 3 Study Dexpramipexole (KNS-760704)
Duration
Patients
Duration
0-1 month
Patients
1
Duration
1-3 months
Patients
0
Duration
3-6 months
Patients
0
Duration
6 months-1 year
Patients
3
Duration
1-2 years
Patients
20
Duration
2 years or more
Patients
1

Adherence


Always
Patients
35
95%
Usually
Patients
2
5%
Sometimes
Patients
0
0%
Never
Patients
0
0%

Burden


Very
Patients
0
0%
Somewhat
Patients
0
0%
A little
Patients
7
19%
Not at all
Patients
30
81%

Cost per month


Cost per month
$200+
Patients
8
28%
Cost per month
$100-199
Patients
0
0%
Cost per month
$50-99
Patients
1
3%
Cost per month
$25-49
Patients
1
3%
Cost per month
< $25
Patients
0
0%
Cost per month
Not specified
Patients
27
93%
Last updated:

6 patient evaluations for ALS Phase 3 Study Dexpramipexole (KNS-760704)

AustinMJ
41200 thumb
AustinMJ
Sex: M
Data Quality: 1 star
Bulbar: none
Arms: mild
Chest: none
Legs: none
I am: g
I have:
ALS

See AustinMJ's full ALS Phase 3 Study Dexpramipexole (KNS-760704) history

Jan 16, 2013 (Started Aug 24, 2011)

  • Perceived effectiveness for ALS (Amyotrophic Lateral Sclerosis): Can’t tell
  • Side Effects: None
  • Adherence: Always
  • Burden: Not at all
Dosage: 300 mg Daily
Cost: Not specified monthly

Nov 26, 2012 (Started Aug 24, 2011)

  • Perceived effectiveness for ALS (Amyotrophic Lateral Sclerosis): Major
  • Side Effects: None
  • Adherence: Always
  • Burden: Not at all
Dosage: 300 mg Daily
Advice & Tips: Been rolled over to open-label for DEX. We hope to have a read-out soon (Dec/Jan) on results. I either have a really slow onset or this drug is really working... maybe both. While I've lost much strength in my right hand, all else is good for the last 2 years. My only negative was an early spike in Liver enzimines...
Cost: Not specified monthly

  • 0 helpful marks
fki2001
20396 thumb
fki2001
Sex: M
Data Quality: 1 star
Bulbar: none
Arms: severe
Chest: moderate
Legs: severe
I am: n
I have:
ALS

See fki2001's full ALS Phase 3 Study Dexpramipexole (KNS-760704) history

Oct 11, 2012 (Started Jun 16, 2011)

  • Perceived effectiveness for Participate in clinical trial: Can’t tell
  • Side Effects: None
  • Adherence: Always
  • Burden: A little
Dosage: 300 mg Daily
Advice & Tips: This was a drug trial, I did'nt know if I had the placibo or the real drug. October 11,2012 the trial ended. They are giving me the real drug while they are analyzing the trial data.

  • 0 helpful marks
Root10996
Portrait default thumb
Root10996
Sex: M
Data Quality: 1 star
Bulbar: none
Arms: severe
Chest: none
Legs: severe
I have:
ALS

See Root10996's full ALS Phase 3 Study Dexpramipexole (KNS-760704) history

Oct 10, 2012 (Started Sep 10, 2011)

  • Perceived effectiveness for Participate in clinical trial: Can’t tell
  • Perceived effectiveness for ALS (Amyotrophic Lateral Sclerosis): Can’t tell
  • Side Effects: None
  • Adherence: Always
  • Burden: Not at all
Dosage: 2 Daily

  • 0 helpful marks
Last updated:
Showing 3 of 6 patient evaluations for ALS Phase 3 Study Dexpramipexole (KNS-760704)